Roby Zomer of MGC Pharma: CannEpil® by Named Patient Request in UK marks a momentous breakthrough
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Roby Zomer, Managing Director & CEO & Rob Clements, Chief Commercial Officer of explains how the availability of CannEpil® by Named Patient Request in the UK marks a momentous breakthrough for the company.
Highlights
· CannEpil®, MGC Pharma's Investigational Medicinal Product ("IMP") is now available in the United Kingdom by Named Patient Request to be prescribed by doctors on The General Medical Council ("GMC") specialist register across the UK.
· The products will be supplied in order to meet the needs of an individual patients where an unmet medical need exists.
· The availability via Named Patient Request follows the announcement that MGC Pharma is providing CannEpil® to an observational trial supported by the I am Billy Foundation.
· CannEpil® is in the process of a clinical development programme for patients suffering from Refractory (or Drug-Resistant) Epilepsy.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.